Skip to main content
XenonStack

XAI

XenonStack Blog AI Drug Discovery and Development: 2027 Guide

and | Published | Updated

AI Drug Discovery and Development: 2027 Guide
16:22

Key takeaway

  • How AI is used across drug discovery and development, what FDA and EMA say, what the evidence shows and the controls leaders need. Not medical advice.

AI helps drug discovery and development at specific, separable stages: finding and validating targets, designing and screening molecules, predicting properties such as ADMET, planning trials and finding existing drugs for new uses. The evidence differs by stage. Protein structure prediction was recognised in the 2024 Nobel Prize in Chemistry, while the first randomised phase 2a trial of a generative-AI-discovered drug, reported in Nature Medicine, 2025, was a 12-week study whose authors say it warrants larger and longer trials. For a related view of AI in clinical imaging, see AI-assisted medical imaging.

For enterprise leaders the question is less "does AI work" and more "where is it credible, what must be controlled and what will a regulator ask for". Regulators have started to answer: the FDA draft guidance on AI to support regulatory decision-making (January 2025) and the EMA and FDA joint principles (January 2026) both centre on a defined context of use and risk-based evidence. This article is general information, not medical or regulatory advice.

Where does AI fit in the drug discovery and development pipeline?

Think of AI as a set of tools placed at different points in a long pipeline, not as one system. The table shows what each stage uses it for and how to read the evidence.

Two-column diagram mapping pipeline stages (target identification, molecule design, ADMET prediction, clinical trials) to controls (context of use, risk-based validation, data lineage, human sign-off).
StageWhat AI is used forTypical methodsHow to read the evidence
Target identificationRanking disease-linked genes and proteins from omics dataMachine learning, graph neural networks, knowledge graphsMethod level. Validate in the laboratory before any programme decision.
Protein structurePredicting 3D structure to inform target and binding studiesDeep learning structure predictionRecognised in the 2024 Nobel Prize in Chemistry (Hassabis and Jumper, with Baker for protein design).
Molecule design and screeningGenerating and scoring candidate moleculesGenerative models, docking with learned scoringOne generative-AI-discovered candidate reached a phase 2a trial (see below). Treat other claims as unproven until published.
ADMET predictionFlagging absorption, toxicity and clearance risks earlyQSAR, ensemble modelsUseful for triage. Predictions still need experimental confirmation.
Clinical trialsPatient matching, protocol simulation, monitoringNLP on records, Bayesian and simulation modelsCovered by regulator expectations on context of use and data quality.
RepurposingFinding new uses for existing drugsKnowledge graphs, similarity search, link predictionGenerates hypotheses, not clinical conclusions.

How does AI help identify and validate drug targets?

Genomic and proteomic data analysis

Machine learning models can sort large genomic and proteomic datasets for patterns linked to disease, which gives scientists a ranked list of candidate targets to test. Structure prediction adds a second input: knowing a protein's shape helps judge whether a small molecule could bind it. The 2024 Nobel Prize in Chemistry recognised protein structure prediction (Demis Hassabis and John Jumper) and computational protein design (David Baker).

Network biology and systems pharmacology

Multi-omics data (genomics, transcriptomics, proteomics, metabolomics) can be represented as a graph of genes, proteins, drugs and diseases. Graph neural networks and knowledge graphs then look for links a human reviewer would miss. The same pattern is described in our post on Graph RAG and knowledge graphs. The output is a hypothesis. Target validation still depends on experiments, and a graph is only as good as the provenance of the data feeding it.

How is AI used in virtual screening, molecular design and ADMET?

Virtual screening and docking

Virtual screening ranks large compound libraries by predicted interaction with a target. AI adds learned scoring functions to docking simulations, which can change the ranking compared with physics-only scoring. The shortlist goes to laboratory assays, so the practical gain is fewer compounds to test, not fewer experiments to run.

De novo design with generative models

Variational autoencoders, generative adversarial networks and reinforcement learning can propose new molecules and optimise them towards goals such as potency and drug-likeness. Generated structures still need to be synthesised, tested and checked for toxicity. Responsible use is covered in our post on responsible AI in healthcare.

ADMET prediction

ADMET stands for absorption, distribution, metabolism, excretion and toxicity. QSAR models and ensemble methods such as random forests and gradient boosting estimate these properties from chemical structure so that weak candidates can be dropped early. Their reliability depends on training data close to the chemistry being tested, so record the applicability domain of each model.

What does the evidence show so far for AI-discovered drugs?

The most useful public reference point is a Nature Medicine, 2025 report titled "A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial". According to the published abstract, participants received rentosertib at one of three regimens or placebo for 12 weeks, adverse event rates were similar across groups, and discontinuations were mainly due to liver toxicity or diarrhoea. The authors conclude that the drug appears safe and well tolerated and that larger, longer trials are warranted.

Read this as an early-stage signal, not as proof of efficacy. A phase 2a trial is small and short, and the result says nothing about the other AI-derived candidates in the industry. Ask any vendor or partner for the peer-reviewed or regulator source behind each claim. For AI use in agentic pharma content and discovery workflows, see Agentic AI in pharma.

How does AI optimise clinical trials?

Patient stratification and recruitment

Natural language processing can read electronic health records and real-world data to flag patients who may meet inclusion criteria, and predictive models can estimate who is likely to complete a protocol. Both uses touch personal health data, so privacy review and a clear context of use come before any model goes near a trial.

Adaptive designs and simulation

Bayesian models and reinforcement learning are used to simulate trial designs and to support mid-trial adjustments set out in the protocol in advance. Any adaptation must be pre-specified and agreed with the regulator. AI does not remove that requirement.

What about personalised medicine and drug repurposing?

Machine learning on genomic and clinical data can suggest biomarkers linked to treatment response, using methods such as support vector machines and deep learning. Knowledge graphs, link prediction and similarity measures such as the Tanimoto coefficient can point to existing drugs worth testing for a new disease. Both produce hypotheses for clinical teams to evaluate. Neither replaces clinical judgement or trial evidence.

What are regulators saying about AI in drug development?

Two regulators have published positions, and both frame AI use around the question it answers and the risk of getting it wrong.

SourceDateWhat it saysStatus
FDA, considerations for AI to support regulatory decision-making for drugs and biologicalsJanuary 2025Recommendations on a risk-based credibility assessment framework for a specific context of useDraft, non-binding. Check the FDA page for the current status.
EMA, reflection paper on AI in the medicines lifecycleConsultation from July 2023Covers AI from drug discovery to post-authorisation. Takes a human-centric approach and advises early regulatory engagement where an AI system may affect benefit-riskReflection paper. EMA's January 2026 page refers to its 2024 paper.
EMA and FDA, Guiding Principles of Good AI Practice in Drug DevelopmentJanuary 2026Ten principles across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoringPrinciples. EMA says additional EU guidance will follow.
FDA, plan on new approach methodologies10 April 2025Encourages computer modelling and AI-based models alongside other methods to reduce animal testing for monoclonal antibodies and other drugsAnnouncement and roadmap.

The ten joint principles, as titled in the Guiding Principles of Good AI Practice in Drug Development, are: human-centric by design; risk-based approach; adherence to standards; clear context of use; multidisciplinary expertise; data governance and documentation; model design and development practices; risk-based performance assessment; life cycle management; and clear, essential information. EMA also publishes its EMA reflection paper on AI in the medicines lifecycle.

What governance, data and cost controls does an AI drug discovery programme need?

The joint principles translate into controls an enterprise can put in place. Each row maps a principle to an operating practice.

ControlWhat it means in practicePrinciple it supports
Context of use registerEach model has a written purpose, scope and the decision it informsClear context of use
Data lineage and documentationRecord where data came from, how it was processed and who approved itData governance and documentation
Risk-tiered validationMore evidence for models that influence safety or efficacy decisionsRisk-based approach and performance assessment
Human reviewA named scientist signs off model-informed decisionsHuman-centric by design
Monitoring and re-evaluationTrack drift when data or chemistry changes and re-test periodicallyLife cycle management
Cost trackingMeter compute and experiment spend per model and per programmeNot a regulator requirement, an enterprise practice

Where agents or automated pipelines touch these steps, the decision trail matters as much as the model. ElixirData Context OS keeps governed context, versioned policy and decision traces in one decision layer above AI agents, and AgentGRC keeps autonomous agent actions inside policy, with the audit trail risk teams need. Related reading: Agentic AI in data governance and compliance and Agentic AI risk management.

How should a pharma or biotech team sequence adoption?

  1. Pick one decision with a clear owner, such as ADMET triage or trial site feasibility, and write its context of use.

  2. Fix the data first: lineage, access rights, privacy review and a documented training set.

  3. Run the model beside the current method and compare results on past, known outcomes before it influences any live decision.

  4. Set the evidence bar by risk, and confirm early with the regulator where the model could affect benefit-risk.

  5. Add monitoring and re-evaluation, then widen to the next stage.

When is AI the wrong tool, and what are the trade-offs?

SituationWhy AI may not fitSafer approach
Little or poor-quality data for the target or chemistryModels extrapolate badly outside their training dataRely on experiments and expert review, collect data first
Decision with direct patient safety impactBlack-box output is hard to justify to a regulatorUse interpretable methods and keep human sign-off
No owner for the model after launchPerformance drifts and nobody noticesAssign life cycle ownership before deployment
Claim cannot be traced to a sourceVendor or internal claims without evidence create riskAsk for the peer-reviewed or regulator source

What will change in AI-enabled drug development over the next 3 to 5 years?

Public sources point to regulation becoming more specific rather than to any single technology jump. EMA states that the January 2026 principles will be supplemented by additional EU guidance, and the FDA guidance from January 2025 is labelled as a draft. Teams that already keep a context-of-use register, data lineage and monitoring records will adapt more easily as these documents are finalised. Trial results for AI-discovered candidates will also accumulate, which is the evidence to watch.

To map one drug-development decision your agents should make, and the context and policy it depends on, book a Context Workshop. See what happens in the workshop.

What should you plan for in 2027?

The points below come from the controls and adoption steps already set out above, and they apply to any programme that uses AI.

  • Write the context of use first. Record each model's purpose, scope and the decision it informs, with a named scientist who signs off.
  • Set the evidence bar by risk. Ask more of models that influence safety or efficacy decisions, and engage the regulator early where benefit and risk could be affected.
  • Keep data lineage and monitoring in place. Track drift, test again periodically and keep documentation that regulators can review.

Teams that already work this way will adapt more easily as guidance develops.

Frequently asked questions

Is AI-discovered drug development proven?

Not broadly. A randomised phase 2a trial of a generative-AI-discovered drug was published in Nature Medicine in 2025. It was a 12-week study, and its authors say larger and longer trials are warranted.

What does the FDA say about AI in drug development?

In January 2025 the FDA published draft, non-binding guidance recommending a risk-based credibility assessment framework for AI used to support regulatory decisions on drug safety, effectiveness or quality. Check the FDA page for current status.

What are the EMA and FDA joint principles?

In January 2026 EMA and the FDA jointly identified ten principles for good AI practice across the medicines lifecycle, including a risk-based approach, a clear context of use, data governance and documentation, and life cycle management.

Does AI replace laboratory experiments?

No. AI narrows candidates and generates hypotheses. Targets, molecules and predictions still need experimental and clinical confirmation.

What should leaders ask before adopting AI in drug discovery?

Ask what decision the model informs, what data it was trained on, what evidence supports it, who reviews its output and how it will be monitored over time.

Next Steps in Drug Discovery and Development

Consult our experts about implementing advanced AI systems and how industries and departments use Decision Intelligence to become decision-centric. Leverage AI to automate and optimize drug discovery and development, enhancing efficiency, precision, and responsiveness.

Follow XenonStack on LinkedIn: XenonStack on LinkedIn for new guides on agentic AI, data and platform engineering.

Ready to put AI agents to work? Explore ElixirClaw, the agentic OS platform to build, orchestrate and govern AI agents.

Table of Contents

navdeep-singh-gill

Navdeep Singh Gill

Global CEO and Founder of XenonStack

LinkedIn profile

Navdeep Singh Gill is serving as Chief Executive Officer and Product Architect at XenonStack. He holds expertise in building SaaS Platform for Decentralised Big Data management and Governance, AI Marketplace for Operationalising and Scaling. His incredible experience in AI Technologies and Big Data Engineering thrills him to write about different use cases and its approach to solutions.

Get the latest articles in your inbox

Subscribe Now

Interested in solving your challenges with the XenonStack team?
Get Started

Tell us about you and your priorities so we can prepare the right conversation. It takes about 2 minutes.

Please Select your Industry
Banking
Fintech
Payment Providers
Wealth Management
Discrete Manufacturing
Semiconductor
Machinery Manufacturing / Automation
Appliances / Electrical / Electronics
Elevator Manufacturing
Defense & Space Manufacturing
Computers & Electronics / Industrial Machinery
Motor Vehicle Manufacturing
Food and Beverages
Distillery & Wines
Beverages
Shipping
Logistics
Mobility (EV / Public Transport)
Energy & Utilities
Hospitality
Digital Gaming Platforms
SportsTech with AI
Public Safety - Explosives
Public Safety - Firefighting
Public Safety - Surveillance
Public Safety - Others
Media Platforms
City Operations
Airlines & Aviation
Defense Warfare & Drones
Robotics Engineering
Drones Manufacturing
AI Labs for Colleges
AI MSP / Quantum / AGI Institutes
Retail Apparel and Fashion

Continue